Johnson & Johnson Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments
Johnson & Johnson (JNJ) reported Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments of -$19.00 million for the 3-month period ending 2018-04-01, per its 10-Q filed 2018-05-01.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments · last filed 2018-05-01
- Johnson & Johnson gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2018-04-01 was -$19.00M.
- Johnson & Johnson gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2017-12-31 was -$27.00M.
- Johnson & Johnson gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2017-10-01 was -$12.00M, a 134.29% decline year-over-year.
- Johnson & Johnson gain (loss) on foreign currency derivative instruments not designated as hedging instruments for the quarter ending 2017-07-02 was $63.00M.
- Johnson & Johnson gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2017 was -$5.00M.
- Johnson & Johnson gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2017 was -$56.00M.
- Johnson & Johnson gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2016 was -$34.00M, a 780.00% decline from fiscal 2014.
- Johnson & Johnson gain (loss) on foreign currency derivative instruments not designated as hedging instruments for fiscal 2014 was $5.00M, a 84.38% decline from fiscal 2013.
| Period end | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 3 month | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 6 month | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 9 month | Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments 12 month |
|---|---|---|---|---|
| 2018-04-01 | -$19.00M 10-Q · filed 2018-05-01 | -$46.00M derived: sum of 2 quarters · filed 2018-05-01 | -$58.00M derived: sum of 3 quarters · filed 2018-05-01 | $5.00M derived: sum of 4 quarters · filed 2018-05-01 |
| 2017-12-31 | -$27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | -$39.00M derived: sum of 2 quarters · filed 2018-02-21 | $24.00M derived: sum of 3 quarters · filed 2018-02-21 | -$5.00M 10-K · filed 2018-02-21 |
| 2017-10-01 | -$12.00M 10-Q · filed 2017-11-02 | $51.00M derived: sum of 2 quarters · filed 2017-11-02 | $22.00M 10-Q · filed 2017-11-02 | -$28.00M derived: sum of 4 quarters · filed 2018-05-01 |
| 2017-07-02 | $63.00M 10-Q · filed 2017-08-03 | $34.00M 10-Q · filed 2017-08-03 | -$16.00M derived: sum of 3 quarters · filed 2018-05-01 | $19.00M derived: sum of 4 quarters · filed 2018-05-01 |
| 2017-04-02 | -$29.00M 10-Q · filed 2018-05-01 | -$79.00M derived: sum of 2 quarters · filed 2018-05-01 | -$44.00M derived: sum of 3 quarters · filed 2018-05-01 | -$80.00M derived: sum of 4 quarters · filed 2018-05-01 |
| 2017-01-01 | -$50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | -$15.00M derived: sum of 2 quarters · filed 2018-02-21 | -$51.00M derived: sum of 3 quarters · filed 2018-02-21 | -$56.00M 10-K · filed 2018-02-21 |
| 2016-10-02 | $35.00M 10-Q · filed 2017-11-02 | -$1.00M derived: sum of 2 quarters · filed 2017-11-02 | -$6.00M 10-Q · filed 2017-11-02 | -$72.00M derived: sum of 4 quarters · filed 2017-11-02 |
| 2016-07-03 | -$36.00M 10-Q · filed 2017-08-03 | -$41.00M 10-Q · filed 2017-08-03 | -$107.00M derived: sum of 3 quarters · filed 2017-08-03 | -$115.00M derived: sum of 4 quarters · filed 2017-08-03 |
| 2016-04-03 | -$5.00M 10-Q · filed 2017-05-08 | -$71.00M derived: sum of 2 quarters · filed 2017-05-08 | -$79.00M derived: sum of 3 quarters · filed 2017-05-08 | $45.00M derived: sum of 4 quarters · filed 2017-05-08 |
| 2016-01-03 | -$66.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$74.00M derived: sum of 2 quarters · filed 2017-02-27 | $50.00M derived: sum of 3 quarters · filed 2017-02-27 | -$34.00M 10-K · filed 2017-02-27 |
| 2015-09-27 | -$8.00M 10-Q · filed 2016-11-04 | $116.00M derived: sum of 2 quarters · filed 2016-11-04 | $32.00M 10-Q · filed 2016-11-04 | $85.00M derived: sum of 4 quarters · filed 2016-11-04 |
| 2015-06-28 | $124.00M 10-Q · filed 2016-08-04 | $40.00M 10-Q · filed 2016-08-04 | $93.00M derived: sum of 3 quarters · filed 2016-08-04 | $91.00M derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-03-29 | -$84.00M 10-Q · filed 2016-05-10 | -$31.00M derived: sum of 2 quarters · filed 2016-05-10 | -$33.00M derived: sum of 3 quarters · filed 2016-05-10 | -$88.00M derived: sum of 4 quarters · filed 2016-05-10 |
| 2014-12-28 | $53.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | $51.00M derived: sum of 2 quarters · filed 2016-02-24 | -$4.00M derived: sum of 3 quarters · filed 2016-02-24 | $5.00M 10-K · filed 2016-02-24 |
| 2014-09-28 | -$2.00M 10-Q · filed 2015-10-30 | -$57.00M derived: sum of 2 quarters · filed 2015-10-30 | -$48.00M 10-Q · filed 2015-10-30 | -$66.00M derived: sum of 4 quarters · filed 2015-10-30 |
| 2014-06-29 | -$55.00M 10-Q · filed 2015-07-31 | -$46.00M 10-Q · filed 2015-07-31 | -$64.00M derived: sum of 3 quarters · filed 2015-07-31 | -$64.00M derived: sum of 4 quarters · filed 2015-07-31 |
| 2014-03-30 | $9.00M 10-Q · filed 2015-05-01 | -$9.00M derived: sum of 2 quarters · filed 2015-05-01 | -$9.00M derived: sum of 3 quarters · filed 2015-05-01 | $85.00M derived: sum of 4 quarters · filed 2015-05-01 |
| 2013-12-29 | -$18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | -$18.00M derived: sum of 2 quarters · filed 2015-02-24 | $76.00M derived: sum of 3 quarters · filed 2015-02-24 | $32.00M 10-K · filed 2015-02-24 |
| 2013-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $94.00M derived: sum of 2 quarters · filed 2014-10-30 | $50.00M 10-Q · filed 2014-10-30 | $89.00M derived: sum of 4 quarters · filed 2014-10-30 |
| 2013-06-30 | $94.00M 10-Q · filed 2014-08-01 | $50.00M 10-Q · filed 2014-08-01 | $89.00M derived: sum of 3 quarters · filed 2014-08-01 | $124.00M derived: sum of 4 quarters · filed 2014-08-01 |
| 2013-03-31 | -$44.00M 10-Q · filed 2014-05-02 | -$5.00M derived: sum of 2 quarters · filed 2014-05-02 | $30.00M derived: sum of 3 quarters · filed 2014-05-02 | $13.00M derived: sum of 4 quarters · filed 2014-05-02 |
| 2012-12-30 | $39.00M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-21 | $74.00M derived: sum of 2 quarters · filed 2014-02-21 | $57.00M derived: sum of 3 quarters · filed 2014-02-21 | $48.00M 10-K · filed 2014-02-21 |
| 2012-09-30 | $35.00M 10-Q · filed 2013-11-04 | $18.00M derived: sum of 2 quarters · filed 2013-11-04 | $9.00M 10-Q · filed 2013-11-04 | -$12.00M derived: sum of 4 quarters · filed 2013-11-04 |
| 2012-07-01 | -$17.00M 10-Q · filed 2013-08-01 | -$26.00M 10-Q · filed 2013-08-01 | -$47.00M derived: sum of 3 quarters · filed 2013-08-01 | -$57.00M derived: sum of 4 quarters · filed 2013-08-01 |
| 2012-04-01 | -$9.00M 10-Q · filed 2013-05-03 | -$30.00M derived: sum of 2 quarters · filed 2013-05-03 | -$40.00M derived: sum of 3 quarters · filed 2013-05-03 | -$47.00M derived: sum of 4 quarters · filed 2013-05-03 |
| 2012-01-01 | -$21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-22 | -$31.00M derived: sum of 2 quarters · filed 2013-02-22 | -$38.00M derived: sum of 3 quarters · filed 2013-02-22 | -$23.00M 10-K · filed 2013-02-22 |
| 2011-10-02 | -$10.00M 10-Q · filed 2012-11-09 | -$17.00M derived: sum of 2 quarters · filed 2012-11-09 | -$2.00M 10-Q · filed 2012-11-09 | -$83.00M derived: sum of 4 quarters · filed 2012-11-09 |
| 2011-07-03 | -$7.00M 10-Q · filed 2012-08-02 | $8.00M 10-Q · filed 2012-08-02 | -$73.00M derived: sum of 3 quarters · filed 2012-08-02 | $46.00M derived: sum of 4 quarters · filed 2012-08-02 |
| 2011-04-03 | $15.00M 10-Q · filed 2012-05-07 | -$66.00M derived: sum of 2 quarters · filed 2012-05-07 | $53.00M derived: sum of 3 quarters · filed 2012-05-07 | $32.00M derived: sum of 4 quarters · filed 2012-05-07 |
| 2011-01-02 | -$81.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $38.00M derived: sum of 2 quarters · filed 2012-02-23 | $17.00M derived: sum of 3 quarters · filed 2012-02-23 | -$31.00M 10-K · filed 2012-02-23 |
| 2010-10-03 | $119.00M 10-Q · filed 2011-11-08 | $98.00M derived: sum of 2 quarters · filed 2011-11-08 | $50.00M 10-Q · filed 2011-11-08 | $51.00M derived: sum of 4 quarters · filed 2011-11-08 |
| 2010-07-04 | -$21.00M 10-Q · filed 2011-08-09 | -$69.00M 10-Q · filed 2011-08-09 | -$68.00M derived: sum of 3 quarters · filed 2011-08-09 | -$52.00M derived: sum of 4 quarters · filed 2011-08-09 |
| 2010-04-04 | -$48.00M 10-Q · filed 2011-05-10 | -$47.00M derived: sum of 2 quarters · filed 2011-05-10 | -$31.00M derived: sum of 3 quarters · filed 2011-05-10 | -$21.00M derived: sum of 4 quarters · filed 2011-05-10 |
| 2010-01-03 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $17.00M derived: sum of 2 quarters · filed 2011-02-25 | $27.00M derived: sum of 3 quarters · filed 2011-02-25 | $21.00M 10-K · filed 2011-02-25 |
| 2009-09-27 | $16.00M 10-Q · filed 2010-11-10 | $26.00M derived: sum of 2 quarters · filed 2010-11-10 | $20.00M 10-Q · filed 2010-11-10 | |
| 2009-06-28 | $10.00M 10-Q · filed 2010-08-11 | $4.00M 10-Q · filed 2010-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |